CD8A and neoplasm: In advanced AML tumor models where PD-1+TIM-3+ CD8+ cells have been correlated with disease progression, dual therapy with anti-PDL-1 and TIM-3Ig has been shown to significantly decrease tumor burden and improve survival [86].